Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.33 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GALR3 | O60755 | 1/20 | 0.32 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11071975 | 0.87 | AR (0.45) | ARMAOAMAOBCYP3A4CYP2C9 | |
| SCHEMBL1710696 | 0.83 | MAOA (0.44) | MAOAMAOBCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1722194 | 0.82 | LTB4R (0.34) | MAOALTB4RCYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1710887 | 0.81 | LMNA (0.33) | MAOALTB4RLMNAHIF1AGALR3 | |
| SCHEMBL1722205 | 0.80 | — | — | |
| SCHEMBL1710869 | 0.80 | MAOA (0.41) | ARMAOAMAOBLTB4RCYP3A4 | |
| SCHEMBL3390734 | 0.80 | MAOA (0.41) | ARMAOAMAOBLTB4RCYP3A4 | |
| SCHEMBL1710510 | 0.79 | CYSLTR2 (0.33) | ARCYSLTR2CYSLTR1 | |
| SCHEMBL16084811 | 0.77 | ALOX5 (0.46) | LTB4RCYP3A4CYP2C9CYP2C19LMNA | |
| SCHEMBL1710567 | 0.77 | MAOB (0.49) | MAOAMAOBCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102203058-B | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2014-11-12 | — | — | CN | disclosed |
| CN-102203058-A | Sulfur-linked compounds for the treatment of ophthalmic diseases and disorders | ACUCELA INC | 2011-09-28 | — | — | CN | disclosed |
| EP-2344451-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010028088-A2 | SULFUR-LINKED COMPOUNDS FOR TREATING OPTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093865-A1 | SULPHUR-LINKED COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ALDH1A2, MPST, CLN6 | AR 4092/4885MAOA 3658/4885MAOB 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.